Journal Watch · Journal of Medicinal Chemistry · 2026

Discovery of LG-NE-29: An Orally Bioavailable GSPT1 Molecular Glue Degrader Effective in Glioblastoma Xenograft Models.

Collectively, these findings validate GSPT1 as an actionable therapeutic target in GBM and establish LG-NE-29 as a robust pharmacological tool for further targeted protein degradation research.

Shi T, Pei Y, Peng B et al.Journal of Medicinal Chemistry3 min readPharma relevance 85/100

DOI: 10.1021/acs.jmedchem.6c00544PMID: 42911697Study type: preclinical (animal / model) study

TL;DR

Collectively, these findings validate GSPT1 as an actionable therapeutic target in GBM and establish LG-NE-29 as a robust pharmacological tool for further targeted protein degradation research.

Key findings

  • In U87MG xenograft models, oral administration of LG-NE-29 induced significant tumor regression.
  • Collectively, these findings validate GSPT1 as an actionable therapeutic target in GBM and establish LG-NE-29 as a robust pharmacological tool for further targeted protein degradation research.

Numbers at a glance (from the abstract)

76%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

This compound efficiently promotes CRBN-dependent ubiquitination and subsequent proteasomal degradation of GSPT1. LG-NE-29 overcomes the metabolic liabilities of early-generation scaffolds, exhibiting an optimized pharmacokinetic profile highlighted by excellent oral bioavailability (F = 76%). Mechanistically, GSPT1 depletion triggers a profound integrated stress response and intrinsic apoptosis.

Full abstract (original)

Background: The clinical management of glioblastoma (GBM) is severely hindered by rapid resistance to temozolomide (TMZ). Through viability-based phenotypic screening, we identified the translation termination factor GSPT1 (G1 to S phase transition 1) as a critical vulnerability in GBM cells. Structure-activity relationship optimization of an isoindolinone scaffold, specifically focused on improving metabolic stability, led to the discovery of LG-NE-29, a potent molecular glue degrader.

What they did: This compound efficiently promotes CRBN-dependent ubiquitination and subsequent proteasomal degradation of GSPT1. LG-NE-29 overcomes the metabolic liabilities of early-generation scaffolds, exhibiting an optimized pharmacokinetic profile highlighted by excellent oral bioavailability (F = 76%). Mechanistically, GSPT1 depletion triggers a profound integrated stress response and intrinsic apoptosis.

Results & conclusions: In U87MG xenograft models, oral administration of LG-NE-29 induced significant tumor regression. Collectively, these findings validate GSPT1 as an actionable therapeutic target in GBM and establish LG-NE-29 as a robust pharmacological tool for further targeted protein degradation research.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c00544 · PubMed 42911697.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

Collectively, these findings validate GSPT1 as an actionable therapeutic target in GBM and establish LG-NE-29 as a robust pharmacological tool for further targeted protein degradation research.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. This compound efficiently promotes CRBN-dependent ubiquitination and subsequent proteasomal degradation of GSPT1.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.6c00544. PubMed ID: 42911697. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Shi T, Pei Y, Peng B et al.. Discovery of LG-NE-29: An Orally Bioavailable GSPT1 Molecular Glue Degrader Effective in Glioblastoma Xenograft Models.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.6c00544.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/discovery-of-lg-ne-29-an-orally-bioavailable-gspt1-molecular-glue-degrad-c00544/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides